NCT06808009View on ClinicalTrials.gov

Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Acute on Chronic Liver Failure

Interventions

DRUG

Lactulose

Syp lactulose

DRUG

Rifaximin

OTHER

Standard Medical treatment

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06808009 - Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial) | Biotech Hunter | Biotech Hunter